The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial

BACKGROUND: Prior randomized clinical trials have reported benefit of fluvoxamine ≥200 mg/d vs placebo for patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: This randomized, double-blind, placebo-controlled, fully remote multisite clinical trial evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiersen, Angela M, Mattar, Caline, Bender Ignacio, Rachel A, Boulware, David R, Lee, Todd C, Hess, Rachel, Lankowski, Alexander J, McDonald, Emily G, Miller, J Philip, Powderly, William G, Pullen, Matthew F, Rado, Jeffrey T, Rich, Michael W, Schiffer, Joshua T, Schweiger, Julie, Spivak, Adam M, Stevens, Angela, Vigod, Simone N, Agarwal, Payal, Yang, Lei, Yingling, Michael, Gettinger, Torie R, Zorumski, Charles F, Lenze, Eric J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445518/
https://www.ncbi.nlm.nih.gov/pubmed/37622035
http://dx.doi.org/10.1093/ofid/ofad419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445518/
https://www.ncbi.nlm.nih.gov/pubmed/37622035
http://dx.doi.org/10.1093/ofid/ofad419

Ejemplares similares